Multiple Sclerosis

Clemastine fumarate, an over-the-counter drug used to fight allergies, can also treat vision damage in patients with multiple sclerosis (MS).

During pregnancy, a mother's vitamin D deficiency may increase her child's risk for multiple sclerosis.

Multiple sclerosis patients may exhibit taste sensory deficits more often than previously understood, according to findings published in the Journal of Neurology.

It is now more possible to predict which individuals will develop multiple sclerosis (MS), according to findings published in the Annals of Neurology.

Researchers assessed 40 patients, 10 of whom of had MS, in order to test whether MRI scans were able to differentiate MS from microangiopathic brain lesions. The researchers believed the MRIs would be able to conduct a special scan called T2 weighted imaging, which identifies white matter.

Patients taking natalizumab may be more susceptible to John Cunningham virus-related problems, potentially increasing their risk for developing progressive multifocal leukoencephalopathy.

Researchers say that platelet activator factor receptors are to blame for the cognitive issues that multiple sclerosis patients develop as their disease progresses.

Metformin and pioglitazone could be beneficial for patients with multiple sclerosis and metabolic syndrome, researchers in Argentina report.

The anticonvulsant drug phenytoin may protect neural tissue in patients with optic neuritis, a common symptom of multiple sclerosis.

Study results indicate the protein regulator Trabid may be a promising target for developing novel treatments for patients with multiple sclerosis.

Since its early days the public perception of multiple sclerosis has changed dramatically which has helped doctors better treat the condition. Even still more work remains to be done to help more people navigate the challenges associated with diagnosis and treatment.

From the initial diagnosis to finding a specialist to better manage the treatment of multiple sclerosis there is a lot that patients need to do in order to maintain as high a quality of life as possible. There are also potential issues patients can encounter all along the way that need to be overcome.

Patients with the relapsing form of multiple sclerosis have a variety of treatment options available to them. For those where the condition has moved into the progressive form there are no easy answers and even more questions remaining to be answered.

When some of the top minds in the field of multiple sclerosis came together in New Orleans it provided an opportunity to see where patient care stood and what could be done to help continue moving things forward for the future.

After receiving breakthrough therapy designation from the US Food and Drug Administration Ocrelizumab cleared another major hurdle in becoming the first treatment approved for progressive multiple sclerosis but more work remains before any potential approval is finalized.